This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sidwell, R. W.
Right arrow Articles by Furuta, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sidwell, R. W.
Right arrow Articles by Furuta, Y.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2007, p. 845-851, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01051-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Efficacy of Orally Administered T-705 on Lethal Avian Influenza A (H5N1) Virus Infections in Mice{triangledown}

Robert W. Sidwell,1* Dale L. Barnard,1 Craig W. Day,1 Donald F. Smee,1 Kevin W. Bailey,1 Min-Hui Wong,1 John D. Morrey,1 and Yousuke Furuta2

Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, Utah 84322-5600,1 Toyama Chemical Co., Ltd., 3-2-5 Nishishinjuku, Tokyo, Japan2

Received 21 August 2006/ Returned for modification 25 September 2006/ Accepted 8 December 2006

T-705 (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) was inhibitory to four strains of avian H5N1 influenza virus in MDCK cells, with the 90% effective concentrations ranging from 1.3 to 7.7 µM, as determined by a virus yield reduction assay. The efficacy was less than that exerted by oseltamivir carboxylate or zanamivir but was greater than that exerted by ribavirin. Experiments with mice lethally infected with influenza A/Duck/MN/1525/81 (H5N1) virus showed that T-705 administered per os once, twice, or four times daily for 5 days beginning 1 h after virus exposure was highly inhibitory to the infection. Dosages from 30 to 300 mg/kg of body weight/day were well tolerated; each prevented death, lessened the decline of arterial oxygen saturation (SaO2), and inhibited lung consolidation and lung virus titers. Dosages from 30 to 300 mg/kg/day administered once or twice daily also significantly prevented the death of the mice. Oseltamivir (20 mg/kg/day), administered per os twice daily for 5 days, was tested in parallel in two experiments; it was only weakly effective against the infection. The four-times-daily T-705 treatments at 300 mg/kg/day could be delayed until 96 h after virus exposure and still significantly inhibit the infection. Single T-705 treatments administered up to 60 h after virus exposure also prevented death and the decline of SaO2. Characterization of the pathogenesis of the duck influenza H5N1 virus used in these studies was undertaken; although the virus was highly pathogenic to mice, it was less neurotropic than has been described for clinical isolates of the H5N1 virus. These data indicate that T-705 may be useful for the treatment of avian influenza virus infections.

* Corresponding author. Mailing address: Institute for Antiviral Research, Utah State University, 5600 Old Main Hill, Logan, UT 84322-5600. Phone: (435) 797-1902. Fax: (435) 797-3959. E-mail: Rsidwell{at}cc.usu.edu.

{triangledown} Published ahead of print on 28 December 2006.

Antimicrobial Agents and Chemotherapy, March 2007, p. 845-851, Vol. 51, No. 3
0066-4804/07/$08.00+0     doi:10.1128/AAC.01051-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Shih, S.-R., Horng, J.-T., Poon, L. L. M., Chen, T.-C., Yeh, J.-Y., Hsieh, H.-P., Tseng, S.-N., Chiang, C., Li, W.-L., Chao, Y.-S., Hsu, J. T.-A. (2009). BPR2-D2 targeting viral ribonucleoprotein complex-associated function inhibits oseltamivir-resistant influenza viruses. J Antimicrob Chemother 0: dkp393v1-dkp393 [Abstract] [Full Text]  
  • Smee, D. F., Hurst, B. L., Egawa, H., Takahashi, K., Kadota, T., Furuta, Y. (2009). Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells. J Antimicrob Chemother 64: 741-746 [Abstract] [Full Text]  
  • Smee, D. F., Hurst, B. L., Wong, M.-H., Bailey, K. W., Morrey, J. D. (2009). Effects of Double Combinations of Amantadine, Oseltamivir, and Ribavirin on Influenza A (H5N1) Virus Infections in Cell Culture and in Mice. Antimicrob. Agents Chemother. 53: 2120-2128 [Abstract] [Full Text]  
  • Julander, J. G., Shafer, K., Smee, D. F., Morrey, J. D., Furuta, Y. (2009). Activity of T-705 in a Hamster Model of Yellow Fever Virus Infection in Comparison with That of a Chemically Related Compound, T-1106. Antimicrob. Agents Chemother. 53: 202-209 [Abstract] [Full Text]  
  • Zheng, B.-J., Chan, K.-W., Lin, Y.-P., Zhao, G.-Y., Chan, C., Zhang, H.-J., Chen, H.-L., Wong, S. S. Y., Lau, S. K. P., Woo, P. C. Y., Chan, K.-H., Jin, D.-Y., Yuen, K.-Y. (2008). Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc. Natl. Acad. Sci. USA 105: 8091-8096 [Abstract] [Full Text]  
  • Gowen, B. B., Wong, M.-H., Jung, K.-H., Sanders, A. B., Mendenhall, M., Bailey, K. W., Furuta, Y., Sidwell, R. W. (2007). In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus Infections. Antimicrob. Agents Chemother. 51: 3168-3176 [Abstract] [Full Text]  
  • Julander, J. G., Furuta, Y., Shafer, K., Sidwell, R. W. (2007). Activity of T-1106 in a Hamster Model of Yellow Fever Virus Infection. Antimicrob. Agents Chemother. 51: 1962-1966 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»